Abstract
Boron-containing compounds for neutron capture therapy (NCT) can be divided into three groups: compounds without specific accumulation in tumor, tumor-selective compounds, and compounds capable of incorporating into the structure of tumor cells. For the NCT of cancer patients, sodium mercaptododecaborate (BSH) and p-boronophenylalanine (BPA) were selected from several hundred of boron-containing compounds. In this paper, data on the distribution of BSH and BPAin the organism of animals with model tumors modeling those encountered in oncological patients are reviewed. Methods for increasing the boron uptake in tumor, based on the combined use of boron compounds and modification factors such as hyperthermia, effect of electric pulses on the tumor zone, administration of compounds possessing vasodilating properties and influencing the blood-brain barrier permeability, are considered.
Similar content being viewed by others
References
R. A. Spryshkova, A. S. Yagudov, E. Yu. Grigor’eva, et al., Vopr. Onkol., 41(2), 106–107 (1995).
M. F. Hawthome, Molec. Med. Today, April, 174–181 (1998).
J. L. Shih and R. M. Brugger, Med. Phys., 19(3), 733–744 (1992).
K. Tokuyne, N. Tokita, Y. Akine, et al., Strahlenther Onkol., 176(2), 81–83 (2000).
T. Hartman and J. Carlson, Radiother. Oncol., 31, 61–75 (1994).
A. H. Soloway, W. Tjarks, B. A. Barnum, et al., Chem. Rev., 98, 1515–1562 (1998).
R. G. Fairchild, S. B. Kahl, B. H. Laster, et al., Cancer Res., 50, 4860–4865 (1990).
R. F. Barth and A. H. Soloway, J. Neuro-Oncol., 33(1–2), 3–7 (1997).
T. A. Buchholz, G. E. Laramore, K. J. Stelzer, et al., J. Neuro-Oncol., 33(1–2), 171–178 (1997).
G. E. Laramore, R. Risler, T. W. Griffin, et al., Bull. Cancer / Radiother., 83(Suppl. 1), 191s–197s (1996).
E. Heber, E. L. Kreimann, D. Nigg, et al., in: Research and Development in Neutron Capture Therapy, W. Sauerwein, R. Moss, and A. Witting (eds.), Monduzzi, Essen (2002), pp. 745–749.
V. A. Trivillin, E. M. Heber, M. E. Itoiz, et al., Appl. Radiat. Isot., 61(5), 939–945 (2004).
D. Gabel, Radiother. Oncol., 30, 199–205 (1994).
J. A. Coderre, J. D. Glass, R. G. Fairchild, et al., Cancer Res., 50, 138–141 (1990).
J. A. Coderre, J. D. Glass, R. G. Fairchild, et al., Cancer Res., 47, 6377–6383 (1987).
Y. Mishima, M. Ichihashi, M. Tsuji, et al., J. Invest. Dermatol., 92(5) (Suppl.), 321s–325s (1989).
W. H. Sweet, J. Neuro-Oncol., 33(1–2), 19–26 (1997).
R. F. Barth, A. H. Soloway, and R. M. Brugger, Cancer Invest., 14(6), 534–550 (1996).
S. Chandra, D. Lorey, and D. Smith, Radiat. Res., 157, 700–710 (2002).
B. Otersen, D. Haritz, F. Grochulla, et al., J. Neuro-Oncol., 33(1–2), 131–139 (1997).
J. Capala, K. Skold, B. H. Stenstam, et al., in: Research and Development in Neutron Capture Therapy, W. Sauerwein, R. Moss, and A. Witting (eds.), Monduzzi, Essen (2002), pp. 1101–1106.
D. E. Callahan, T. M. Forte, S. M. Afzal, et al., Int. J. Radiat. Oncol. Biol. Phys., 45(3), 761–771 (1999).
C. P. Ceberg, A. Brun, S. B. Kahl, et al., J. Neurosurg., 83, 86–92 (1995).
H. Yanagie, H. Kobayashi, Y. Takeda, et al., Biomed. Pharmacother., 56(2), 93–99 (2002).
M. F. Hawthorne and K. Shelly, J. Neuro-Oncol., 33(1–2), 53–58 (1997).
X. Q. Pan, H. Wang, S. Shukla, et al., Bioconjug. Chem., 13, 435–442 (2002).
L. F. Tietze, U. Griesbach, U. Bothe, et al., Chem. Bio. Chem., 3, 219–225 (2002).
L. Liu, R. F. Barth, D. M. Adams, et al., Anticancer Res., 16(5a), 2581–2587 (1996).
H. Yanagia, Y. Fujii, M. Sekiguchi, et al., J. Cancer Res. Clin. Oncol., 120(11), 636–640 (1994).
S. Novick, M. Quastel, S. Marcus, et al., Nucl. Med. Biol., 29(2), 159–167 (2002).
W. Yang, R. F. Barth, D. M. Adams, et al., Cancer Res., 57, 4333–4339 (1997).
K. Schwechheimer, S. Huang, and W. K. Cavenee, Int. J. Cancer, 62, 145–148 (1995).
R. F. Barth, W. Yang, D. Adams, et al., Cancer Res., 62(11), 3159–3166 (2002).
K. Ono, S.-I. Masunaga, M. Suzuki, et al., Int. J. Radiat. Oncol. Biol. Phys., 43(2), 431–436 (1999).
R. F. Barth, W. Yang, J. H. Rotaru, et al., Int. J. Radiat. Oncol. Biol. Phys., 47(1), 209–218 (2000).
V. Gregoire, A. C. Begg, R. Huiskamp, et al., Radiother. Oncol., 27(1), 46–54 (1993).
J.-P. Pignol, H. Oudart, P. Chauvel, et al., Br. J. Radiol., 71, 320–323 (1998).
J. A. Coderre, D. D. Joel, P. L. Micca, et al., Radiat. Res., 129, 290–296 (1992).
M. Cemazar, J. Skrk, B. Mitrovic, et al., Br. J. Radiol., 73, 195–200 (2000).
W. S. Kiger, C. F. Chuang, M. R. Palmer, et al., in: Research and Development in Neutron Capture Therapy, W. Sauerwein, R. Moss, and A. Witting (eds.), Monduzzi, Essen (2002), pp. 765–768.
R. F. Barth, W. Yang, R. T. Bartus, et al., Int. J. Radiat. Oncol. Biol. Phys., 52(3), 858–868 (2002).
W. Yang, R. F. Barth, R. T. Bartus, et al., Neurosurgery, 47(1), 189–198 (2000).
R. F. Barth, W. Yang, J. H. Rotaru, et al., Cancer Res., 57(6), 1129–1136 (1997).
S. Masunaga, K. Ono, M. Suzuki, et al., Br. J. Radiol., 70, 391–398 (1997).
M. R. Horsman, P. J. Wood, D. J. Chaplin, et al., Radiother. Oncol., 18, 49–57 (1990).
K. Ono, Y. Kinashi, M. Suzuki, et al., Jpn. J. Cancer Res., 91(8), 853–858 (2000).
Author information
Authors and Affiliations
Additional information
__________
Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 40, No. 11, pp. 3–7, November, 2006.
Rights and permissions
About this article
Cite this article
Koryakin, S.N. Compounds for neutron capture therapy and their distribution in tumors and surrounding tissues of animals (A review). Pharm Chem J 40, 583–587 (2006). https://doi.org/10.1007/s11094-006-0198-0
Received:
Issue Date:
DOI: https://doi.org/10.1007/s11094-006-0198-0